Are chickens the next biologic factory?

At the core of the system is the idea that eggs are already highly optimized biological ‘factories’. They are naturally sterile, self-contained, and evolved to produce and stabilize large amounts of protein. By inserting genes encoding therapeutic proteins into avian cells, the company enables hens to deposit these proteins into egg whites, effectively transforming each egg into a mini bioreactor. 

This approach contrasts with conventional manufacturing, which typically relies on large-scale cell culture systems—such as Chinese hamster ovary (CHO) cells—grown in expensive steel bioreactors. The egg-based platform aims to simplify production, reduce infrastructure needs, and significantly lower costs while improving scalability and supply chain resilience. 
The platform is enabled by recent advances in precision genome engineering, access to large genomic datasets, and the ability to culture and modify avian primordial germ cells. These technologies allow stable and reproducible protein expression in eggs, potentially supporting the production of a wide range of biologics, including monoclonal antibodies. 

However, translating this concept into a reliable manufacturing system comes with challenges. A key hurdle is achieving consistent protein yield and quality at levels required for pharmaceutical production. Scaling from experimental systems to industrial output—and proving that the process can meet regulatory standards—remains an open question. There is also historical skepticism: earlier attempts at egg-based biologics have seen limited success and did not substantially reduce drug costs. 

Neion Bio is advancing the platform through commercial partnerships to produce multiple therapeutic proteins, aiming to demonstrate that eggs can function as a scalable and cost-effective alternative to traditional biomanufacturing systems. 

Picture: Microsurgery of an egg, Neion Bio Inc